Maze Therapeutics (MAZE) Amortization of Deferred Charges (2026)

Maze Therapeutics' (MAZE) quarterly Amortization of Deferred Charges came in at $371000.0 in Q1 2026.

Maze Therapeutics (MAZE) Amortization of Deferred Charges (2026) Analysis & Trends

Maze Therapeutics has disclosed Amortization of Deferred Charges across 1 years of filings, most recently posting $371000.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn
9 Abivax 90.15 Bn 90.15 Bn -
10 Maze Therapeutics 1.31 Bn 1.31 Bn 18.21 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 371,000.00
Mar 31, 2026 371,000.00